Objective
unresectable hepatocellular carcinoma, HCC
SEVER
Edited by: Belgin Sever, Anadolu University, TurkeyReviewed by: Paul Zarogoulidis, Euromedica General Clinic, Greece; Sahin Lacin, Koç University Hospital, TurkeyThis study was aimed to evaluate the efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of unresectable hepatocellular carcinoma and to explore a new therapeutic strategy for the treatment of advanced HCC.